GlaxoSmithKline Updated March 19, 2020 1

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

Call for Grant Applications (CGA) GlaxoSmithKline (GSK) intends to identify and fund innovative, high-quality, independent third-party educational activities that are designed to close healthcare professional (HCP) educational, quality, and performance gaps and improve patient health, enabling patients to Do More, Feel Better, and Live Longer. I. Eligible Organizations Prior to submitting a grant, organizations must first register and be approved as an eligible educational provider. Educational providers must meet the below eligibility criterion:

• Accredited to provide HCP continuing education (ie, CME, CE) by a national accrediting body such as the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), American Nurses Credentialing Center (ANCC), or American Association of Nurse Practitioners (AANP).

Organizations must be fully compliant with the ACCME (and other nationally recognized accrediting body) standards for commercial support and design and deliver all activities (including content, faculty, and speakers) independent from GSK control, influence, and involvement. II. Disease Areas of Interest CGA Details GSK accepts educational grant applications from eligible educational providers in response to a specific CGA. Funding priorities will focus on independent educational initiatives designed to measure improvements/changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*).

Please click on the disease area of interest for more details regarding the specific CGA. GSK Disease Area

of Interest Submit Under

Therapeutic Area Asthma Respiratory Severe Eosinophilic Asthma Respiratory COPD Respiratory Eosinophilic Granulomatosis with Polyangiitis (EGPA) Rare Disease

Systemic Lupus Erythematosus (SLE) Immuno-Inflammation

Multiple Myeloma Oncology

Ovarian Cancer Oncology

GlaxoSmithKline Updated March 19, 2020 2

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

Endometrial Cancer Oncology

Vaccine Preventable Diseases Vaccines

Oral Health Oral Health

Pain-Osteoarthritis Neurology

Pain-Headache Neurology

Influenza Infectious Disease – Non-Vaccines

Smoking Cessation Smoking Cessation III. Grant Review Criteria Grant applications are reviewed based on the following criteria:

1. Compliance Grant requests are assessed for completeness of the application; compliance with all applicable laws, policies, and guidelines; and project management plan and budget.

1.1 Compliant with guidelines for IME/CME 1.2 Free of commercial bias/influence, non-promotional, and fair balanced 1.3 Budget costs are reasonable and customary 1.4 No GSK funds are used for food, beverage, meals, travel, or accommodation

costs for attendees Please do not include specific faculty names in the submitted grant applications.

2. Disease Area Alignment Grant requests are prioritized based on optimal alignment with patient needs, HCP performance gaps, healthcare system quality gaps, and GSK clinical interests.

2.1 Aligns with GSK's clinical disease interests

3. Needs Assessment/Gaps Grant requests should include an independent, evidence-based needs assessment that identifies the knowledge, competence, performance, and/or patient/community health gaps that exist. Utilization of multiple methods of assessing learning needs and gaps between current practice and evidence-based best practice provides an accurate and balanced prospective.

3.1 Needs assessment is independent, evidence-based, and scientifically/medically accurate; educational/quality/professional practice gaps have been identified

3.2 Educational/quality/professional practice gaps are HCP knowledge, competence, performance, and/or patient/community health

3.3 Strategy used to identify needs/gaps (eg, survey/interview; focus group; peer-review published data; nationally recognized consensus sources for clinical performance/quality measures such as AHRQ, NCQA, NQF, PCPI, CMS-PQRS; patient chart/EHR data; medical claims data, etc)

GlaxoSmithKline Updated March 19, 2020 3

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

4. Learning Objectives/Educational Design Grant requests should provide measurable learning objectives that are aligned with the identified needs and expected improvements of the target audience. Bringing HCPs from various disciplines together in tailored learning environments can enable participants to learn both individually and as collaborative members of the healthcare team, with a common goal of improving patient health.

4.1 Learning objectives are measurable and designed to close identified gaps 4.2 Educational design is interactive and considers appropriate target audience

(including collaborative members of the healthcare team and patients, as appropriate) and learning preferences

4.3 For curriculum-based initiatives, educational design incorporates an organized and hands-on approach to guide learners through longitudinal curriculum that focuses on performance/quality improvement (as appropriate)

4.4 Strategy to enhance change (eg, tools that support application of knowledge into practice such as algorithms, patient compliance materials, office compliance tools, reminder systems, patient feedback, system changes, etc) has been included to reinforce learning (as appropriate)

5. Educational Outcomes Grant requests should have a strategic plan to measure educational outcomes. Using Moore’s 2009 expanded educational outcomes framework*, initiatives that are designed to measure improvements/changes in HCP knowledge and higher (Levels 3-7*) are funding priorities.

5.1 Strategic plan to measure educational outcomes is realistic for the scope of the initiative and designed to measure if the learning objectives were achieved

5.2 Overall initiative is designed to measure changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*)

5.3 Strategy used to evaluate effectiveness of initiative (eg, direct and objective assessments, audience response system, pre/post tests, case studies, chart audits, patient surveys, EHR data, disease screening audits, medical claims data, etc)

5.4 Publication or communication strategy is designed for dissemination of educational outcomes results so that best practices and ways to improve can be shared to further improve patient health

IV. Conflicts of Interest Conflicts of interest must be identified and resolved. The educational provider is required to show that any organization, group, or individual who is in a position to control the content of an educational activity has disclosed all relevant financial relationships with any commercial interest. This includes, but is not limited to, educational partners and any of its affiliates, subsidiaries, or parent company. GSK accepts the ACCME’s definition of “‘relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Failure to disclose and resolve all known conflicts of interest will disqualify the grant requestor.

GlaxoSmithKline Updated March 19, 2020 4

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

V. Terms and Conditions 1. Grants should be submitted via the GSK website: www.GSKgrants.com 2. This CGA does not commit GSK to award a grant or to pay any costs incurred in

the preparation of a response to this request. 3. GSK reserves the right to accept or reject any or all applications received as a

result of this request or to cancel in part or in its entirety this CGA at any time without prior notification or permission.

4. GSK reserves the right to post submissions and announce the details of successful grant applications by whatever means ensures transparency, such as on GSK’s website, in presentations, and/or in other public media.

5. All communications about the CGA must come exclusively to GSK US Medical Affairs. Failure to comply may disqualify providers from receiving future grants.

VI. Transparency Consistent with our commitment to transparency and in accordance with statutory requirements, GSK reports funded educational grants in the US. GSK reserves the right to post submissions and results on our website. Per GSK's Letter of Agreement, GSK funds are not permitted to defray or pay any costs for food, beverage, meals, travel, or accommodations for program attendees.

GlaxoSmithKline Updated March 19, 2020 5

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

ASTHMA Please refer to Section III Grant Review Criteria (above) for more details about how grant applications will be reviewed.

Timeline: Grants may be submitted between November 18, 2019 and March 2, 2020, with a grant start date of May 15, 2020 or later.

Healthcare Gap(s): Our intent is to fund educational initiatives that are designed to address at least 1 of the following independently identified healthcare gaps; however, other independently identified healthcare gaps are also encouraged to be included: (1) Burden of disease—how to recognize patients who are still symptomatic

despite ICS/LABA treatment and who are not candidates for biologic therapy1,2

(2) Choice of pharmacotherapy in asthmatic (non-eosinophilic) patients with moderate/severe asthma1-3

(3) The impact of inhaler adherence on asthma outcomes4,5 (4) Asthma pathophysiology3 (5) Patient-reported outcomes and alternate control questionnaires6

More Information: Our intent is to fund educational initiatives that use multi-channel platforms and reach a national audience. Educational initiatives at a national respiratory conference will be considered. Preference is for educational initiatives that are accredited (eg, by the ACCME, ANCC, ACPE, AANP, AAPA, etc).

Educational Outcomes:

Grants that are designed to measure improvements/changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*) are funding priorities.

Budget Available: Grant requests up to $250K will be considered for funding. The total available budget for this CGA is $500K.

References: 1. US National Heart, Lung, and Blood Institute (NHLBI) National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007. http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf

2. Levy, BD, Noel, PJ, Freemer MM, et al. Am J Respir Crit Care Med. 2015;192:1366-1372. http://dx.doi.org/10.1164/rccm.201505-0963WS

3. Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention. 2015. http://www.ginasthma.org/

4. Melani AS, Canessa P, Coloretti I, et al. Respir Med. 2012;106:668-676. http://dx.doi.org/10.1016/j.rmed.2011.11.016

5. Fink JB, Rubin BK. Respir Care. 2005;50:1360-1374. doi 6. Ahmed S, Berzon RA, Revicki DA, et al. Med Care. 2012;50:1060-1070.

http://dx.doi.org/10.1097/MLR.0b013e318268aaff

GlaxoSmithKline Updated March 19, 2020 6

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

SEVERE EOSINOPHILIC ASTHMA Please refer to Section III Grant Review Criteria (above) for more details about how grant applications will be reviewed.

Timeline: Grants may be submitted between November 18, 2019 and March 2, 2020, with a grant start date of May 15, 2020 or later.

Healthcare Gap(s): Our intent is to fund educational initiatives that are designed to close at least 1 of the following independently identified healthcare gaps; however, other independently identified healthcare gaps are also encouraged to be included: (1) Unmet need—the role of IL-5 and eosinophils in severe asthma and

comorbid or associated conditions [eg, nasal polyps (NP), hypereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss)], burden of disease, diagnosis, treatment, and race and ethnicity1-6

(2) Severe eosinophilic asthma pathophysiology, diagnosis, assessment, and treatment1,2,6,7

(3) Choice of pharmacotherapy in asthma with regard to patient subtypes (eg, eosinophilic) and phenotypes or endotypes8,9

(4) Biomarkers of severe asthma disease state, prognosis, and management10,11 More Information: Our intent is to fund educational initiatives that use multi-channel platforms

and reach national and local/regional audiences. Educational initiatives at respiratory conferences will be considered. Preference is for educational initiatives that are accredited (eg, by the ACCME, ANCC, ACPE, AANP, AAPA, etc).

Educational Outcomes:

Grants that are designed to measure improvements/changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*) are funding priorities.

Budget Available: Grant requests up to $300K will be considered for funding. The total available budget for this CGA is $2M.

References: 1. US National Heart, Lung, and Blood Institute (NHLBI) National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007. https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma

2. Levy BD, Noel PJ, Freemer MM, et al. Am J Respir Crit Care Med. 2015;192:1366-1372. http://dx.doi.org/10.1164/rccm.201505-0963WS

3. Groh M, Pagnoux C, Baldini, C, et al. Eur J Intern Med. 2015;26:545-553. http://dx.doi.org/10.1016/j.ejim.2015.04.022

4. Greco A, Rizzo MI, De Virgilio A, et al. Autoimmun Rev. 2015;14:341-348. http://dx.doi.org/10.1016/j.autrev.2014.12.004

5. Landolina NA and Levi-Schaffer F. Current Opin Pharmacol. 2014;17:71-80. http://dx.doi.org/10.1016/j.coph.2014.07.014

6. Global Initiative for Asthma (GINA) Global Strategy for Asthma

GlaxoSmithKline Updated March 19, 2020 7

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

Management and Prevention. 2019. http://www.ginasthma.org/ 7. Chung KF, Wenzel SE, Brozek JL, et al. Eur Respir J. 2014;43:343–373.

http://dx.doi.org/10.1183/09031936.00202013 8. Xie M, Wenzel SE. Chin Med J. 2013;126:166-174.

http://dx.doi.org/10.3760/cma.j.issn.0366-6999.20123023 9. Holgate ST, Walker S, West B, et al. Clin Chest Med. 2019;40:227-241.

http://dx.doi.org/10.1016/j.ccm.2018.10.013 10. Wan XC, Woodruff PG. Immunol Allergy Clin North Am. 2016;36:547-

557. http://doi.org/10.1016/j.iac.2016.03.004 11. Tiotiu A. Asthma Res and Pract. 2018;4:1-10.

http://dx.doi.org/10.1186/s40733-018-0047-4

GlaxoSmithKline Updated March 19, 2020 8

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

COPD Please refer to Section III Grant Review Criteria (above) for more details about how grant applications will be reviewed.

Timeline: Grants may be submitted between November 18, 2019 and March 2, 2020, with a grant start date of May 15, 2020 or later.

Healthcare Gap(s): Our intent is to fund educational initiatives that are designed to close at least 1 of the following independently identified healthcare gaps; however, other independently identified healthcare gaps are also encouraged to be included: (1) Pharmacological approach to COPD management based on treatable traits

of symptom burden and exacerbation risk, focused on the role of dual bronchodilator and triple therapy regimens in COPD1-4

(2) COPD exacerbations: identification, patient burden of moderate and hospitalized exacerbations, and defining patients at risk for future exacerbations5

More Information: Our intent is to fund educational initiatives that use multi-channel platforms and reach a national audience. Educational initiatives at a national respiratory conference will be considered. Preference is for educational initiatives that are accredited (eg, by the ACCME, ANCC, ACPE, AANP, AAPA, etc).

Educational Outcomes:

Grants that are designed to measure improvements/changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*) are funding priorities.

Budget Available: Grant requests up to $250K will be considered for funding. The total available budget for this CGA is $500K.

References: 1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2017. http://www.goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd

2. Rodrigo GJ, Price D, Anzueto A, et al. Int J Chron Obstruct Pulmon Dis. 2017;12: 907-922. http://doi.org/10.2147/COPD.S130482

3. Tashkin DP, Strange C. Int J Chron Obstruct Pulmon Dis. 2018;13:2587-2601. http://doi.org/10.2147/COPD.S172240

4. Lipworth B, Kuo CR, Jabbal S. Int J Chron Obstruct Pulmon Dis. 2018;13:3003-3009. http://doi.org/10.2147/COPD.S177333

5. Anzueto A, Miravitlles M. Am J Med. 2018;131(9S):15-22. http://doi.org/10.1016/j.amjmed.2018.05.003

GlaxoSmithKline Updated March 19, 2020 9

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) Please refer to Section III Grant Review Criteria (above) for more details about how grant applications will be reviewed.

Timeline: Grants may be submitted between November 1, 2019 and March 19, 2020.

Healthcare Gap(s): Our intent is to fund educational initiatives that are designed to close at least 1 of the following independently identified healthcare gaps; however, other independently identified healthcare gaps are also encouraged to be included: (1) The role of eosinophils and IL-5 in EGPA (formerly Churg-Strauss) and

comorbid or associated conditions [eg, hypereosinophilic syndrome (HES), severe eosinophilic asthma (SEA), nasal polyps (NP)]1,2,3

(2) EGPA clinical features, comorbidities, diagnosis, and treatment1,2,4 (3) EGPA pathophysiology2 (4) EGPA patient journey, the association between EGPA and comorbid or

associated conditions (eg, SEA, NP, HES), and burden of disease5,6,7,8 (5) Diagnostic approaches (eg, eosinophilia, differential diagnosis from other

eosinophilic disorders, or ANCA-associated vasculitis)9,10 More Information: Our intent is to fund educational initiatives that use multi-channel platforms

and reach a national, regional, and/or local audience. Educational initiatives at national conferences and regional or local meetings will be considered. Preference is for educational initiatives that are accredited (eg, by the ACCME, ANCC, ACPE, AANP, AAPA, etc).

Educational Outcomes:

Grants that are designed to measure improvements/changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*) are funding priorities.

Budget Available: The total available budget for this CGA is $1.0M. References: 1. Groh M, Pagnoux C, Baldini, C, et al. Eur J Intern Med. 2015;26:545-

553. http://dx.doi.org/10.1016/j.ejim.2015.04.022 2. Greco A, Rizzo MI, De Virgilio A, et al. Autoimmun Rev. 2015;14:341-

348. http://dx.doi.org/10.1016/j.autrev.2014.12.004 3. Landolina NA and Levi-Schaffer F. Curr Opin Pharmacol. 2014;17:71-

80. https://doi.org/10.1016/j.coph.2014.07.014 4. Navarro-Mendoza EP, Tobón GJ. Curr Rheumatol Rep. 2018;20:23.

https://doi.org/10.1007/s11926-018-0736-2 5. Koutantji M, Harrold E, Lane S, et al. Arthritis Care Res. 2003;49:826-

837. http://dx.doi.org/10.1002/art.11471 6. Sokołowska B, Szczeklik W, Piłat O, et al. Clin Rheumatol. 2013;32:779-

785. http://dx.doi.org/10.1007/s10067-013-2169-7 7. Comarmond C, Pagnoux C, Khellaf M, et al. Arthritis Rheum.

2013;65:270-281. https://doi.org/10.1002/art.37721 8. Vaglio A, Buzio C, and Zwerina J. Allergy. 2013;68:261-273.

https://doi.org/10.1111/all.12088 9. Pagnoux, C. Eur J Rheumatol. 2016;3:122-133.

GlaxoSmithKline Updated March 19, 2020 10

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

https://dx.doi.org/10.5152/eurjrheum.2015.0043 10. Mejia R, Nutman TB. Semin Hematol. 2012;49:149-159.

https://doi.org/10.1053/j.seminhematol.2012.01.006

GlaxoSmithKline Updated March 19, 2020 11

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Please refer to Section III Grant Review Criteria (above) for more details about how grant applications will be reviewed.

Timeline: Grants may be submitted between November 18, 2019 and March 2, 2020, with a grant start date of May 15, 2020 or later.

Healthcare Gap(s): Our intent is to fund educational initiatives that are designed to close at least 1 of the following independently identified healthcare gaps; however, other independently identified healthcare gaps are also encouraged to be included: (1) SLE monitoring of disease activity, flare recognition, and long-term

treatment goals1-5 (2) Organ damage; inadequate control (ongoing disease activity or frequent

flares) and excessive corticosteroid use6-11 (3) SLE pathophysiology12,13 (4) Patient-provider communication14,15

More Information: Our intent is to fund educational initiatives for rheumatologists that use multi-channel platforms and reach a national, regional, and/or local audience. Educational initiatives at national conferences and regional or local meetings will be considered. Preference is for educational initiatives that are accredited (eg, by the ACCME, ANCC, AANP, AAPA, etc).

Educational Outcomes:

Grants that are designed to measure improvements/changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*) are funding priorities.

Budget Available: The total available budget for this CGA is $4.0M. References: 1. American College of Rheumatology Ad Hoc Committee on Systemic

Lupus Erythematosus Guidelines. Arthritis Rheum. 1999;42:1785-1796. http://doi.org/10.1002/1529-0131(199909)42:9<1785::AID-ANR1>3.0.CO;2-#

2. Mosca M, Tani C, Bombardieri S, et al. Ann Rheum Dis. 2010;69:1269-1274. https://doi.org/10.1136/ard.2009.117200

3. Petri M, Orbai A, Alarcon GS, et al. Arthritis Rheum. 2012;64:2677-2686. http://doi.org/10.1002/art.34473

4. van Vollenhoven RF, Mosca M, Bertsias G, et al. Ann Rheum Dis. 2014;73:958-967. http://dx.doi.org/10.1136/annrheumdis-2013-205139

5. Doria A, Gatto M, Zen M, et al. Autoimmun Rev. 2014;13:770-777. http://dx.doi.org/10.1016/j.autrev.2014.01.055

6. Bruce IN, O’Keeffe AG, Farewell V, et al. Ann Rheum Dis. 2015;74:1706-1713. http://dx.doi.org/10.1136/annrheumdis-2013-205171

7. Urowitz MB, Gladman DD, Ibanez D, et al. Arthritis Care Res. 2012;64:132-137. http://dx.doi.org/10.1002/acr.20648

8. Sutton EJ, Davidson JE, Bruce IN, et al. Semin Arthritis Rheum. 2013;43:352-361. http://dx.doi.org/10.1016/j.semarthrit.2013.05.003

GlaxoSmithKline Updated March 19, 2020 12

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

9. Gladman DD, Urowitz MB, Rahman P, et al. J Rheumatol. 2003;30:1955-1959. doi

10. Fanouriakis A, Kostopoulou M, Alunno A, et al. Ann Rheum Dis. 2019;78:736-745. http://dx.doi.org/10.1136/annrheumdis-2019-215089

11. Jordan N, Lutalo PM, D'Cruz DP. BMC Med. 2013;11:120. http://dx.doi.org/10.1186/1741-7015-11-120

12. Mok CC, Lau CS. J Clin Pathol. 2003;56:481-490. http://dx.doi.org/10.1136/jcp.56.7.481

13. Cancro MP, D’Cruz DP, Khamashta MA. J Clin Invest. 2009;119:1066-1073. https://doi.org/10.1172/JCI38010

14. Berrios-Rivera JP, Street RL Jr, Garcia Popa-Lisseanu MG, et al. Arthritis Rheum. 2006;55:385-393. http://dx.doi.org/10.1002/art.21988

15. Demas KL and Costenbader KH. Curr Opin Rheumatology 2009;21:102-109. http://dx.doi.org/10.1097/BOR.0b013e328323daad

GlaxoSmithKline Updated March 19, 2020 13

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

MULTIPLE MYELOMA Please refer to Section III Grant Review Criteria (above) for more details about how grant applications will be reviewed.

Timeline: Grants may be submitted starting October 25, 2019. The grant cycle will close when budget is no longer available; we will update the website accordingly. We will aim to communicate decisions within 4 months from the grant submission date.

Healthcare Gap(s): Our intent is to fund educational initiatives that are designed to close at least 1 of the following independently identified healthcare gaps; however, other independently identified healthcare gaps are also encouraged to be included: (1) Multiple Myeloma diagnosis, classification, and clinical features1-3 (2) Therapeutic management of Multiple Myeloma4,5 (3) Therapeutic targets for relapsed/refractory Multiple Myeloma6,7

More Information: Our intent is to fund educational initiatives that use multi-channel platforms and reach a national, regional, and/or local audience. Educational initiatives at national conferences and regional or local meetings will be considered. Preference is for educational initiatives that are accredited (eg, by the ACCME, ANCC, ACPE, AANP, AAPA, etc).

Educational Outcomes:

Grants that are designed to measure improvements/changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*) are funding priorities.

Budget Available: The total available budget for this CGA is $5.0M. References: 1. National Comprehensive Cancer Network Clinical Practice Guidelines in

Oncology. Version 2.2019—April 10, 2019. https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf

2. Rajkumar SV. Am Soc Clin Oncol Educ Book. 2016;35:e418-423. http://dx.doi.org/10.14694/EDBK_159009

3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Version 3.2019—June 19, 2019. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

4. Anderson KC. Clin Cancer Res. 2016;22:5419-5427. http://dx.doi.org/10.1158/1078-0432.CCR-16-0625

5. Castella M, Fernández de Larrea C, Martín-Antonio B. Int J Mol Sci. 2018;19:3613. http://dx.doi.org/10.3390/ijms19113613

6. Chim CS, Kumar SK, Orlowski RZ, et al. Leukemia. 2018;32:252-262. Chim CS, Kumar SK, Orlowski RZ, et al. Leukemia. 2019;33:1058-1059. http://dx.doi.org/doi:10.1038/leu.2017.329 http://dx.doi.org/doi:10.1038/s41375-019-0410-3

7. Laubach J, Garderet L, Mahindra A, et al. Leukemia. 2016;30:1005-1017. http://dx.doi.org/doi:10.1038/leu.2015.356

GlaxoSmithKline Updated March 19, 2020 14

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

OVARIAN CANCER Please refer to Section III Grant Review Criteria (above) for more details about how grant applications will be reviewed.

Timeline: Grants may be submitted starting November 18, 2019. The grant cycle will close when budget is no longer available; we will update the website accordingly. We will aim to communicate decisions within 3 months from the grant submission date.

Healthcare Gap(s): Our intent is to fund educational initiatives that are designed to close at least 1 of the following independently identified healthcare gaps; however, inclusion of other independently identified healthcare gaps is also encouraged: (1) Standard of care for the treatment of ovarian cancer as reflected in

current and evidence-based updates to guidelines1 (2) Rationale for use of PARP inhibitors in the maintenance treatment setting

for recurrent ovarian cancer2,3 (3) Management of treatment-related adverse events associated with the use

of PARP inhibitors4 More Information: Our intent is to fund educational initiatives that use multi-channel platforms

and reach a national audience. Educational initiatives hosted online or held live at national oncology conferences, regional and local meetings, as well as post-conference education, grand rounds, patient-tethered education, and healthcare quality improvement initiatives will be considered. Preference is for educational initiatives that are accredited (eg, by the ACCME, ANCC, ACPE, AANP, AAPA, etc).

Educational Outcomes:

Grants that are designed to measure improvements/changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*) are funding priorities.

Budget Available: The total available budget for this CGA is $4M. References: 1. NCCN Clinical Practice Guidelines In Oncology: Ovarian Cancer

Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2.2019—September 17, 2019. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf

2. Hanker LC, Loibl S, Burchardi, et al. Ann Oncol. 2012;23:2605-2612. https://doi.org/10.1093/annonc/mds203

3. Randall LM, Birrer MJ, Herzog TJ. Oncologist. 2019;24:576-579. https://doi.org/10.1634/theoncologist.2019-0020

4. LaFargue CJ, Dal Molin GZ, Sood AK, et al. Lancet Oncol. 2019; 20:e15-e28. https://doi.org/10.1016/S1470-2045(18)30786-1

GlaxoSmithKline Updated March 19, 2020 15

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

ENDOMETRIAL CANCER Please refer to Section III Grant Review Criteria (above) for more details about how grant applications will be reviewed.

Timeline: Grants may be submitted starting November 18, 2019. The grant cycle will close when budget is no longer available; we will update the website accordingly. We will aim to communicate decisions within 3 months from the grant submission date.

Healthcare Gap(s): Our intent is to fund educational initiatives that are designed to close at least 1 of the following independently identified healthcare gaps; however, other independently identified healthcare gaps are also encouraged to be included: (1) Endometrial cancer disease state education including risk factors and role

of biomarker/molecular testing1-4 (2) Therapeutic management of endometrial cancer1,2,5 (3) Adverse events related to treatment, including early identification,

management, and patient education and counseling6,7 More Information: Our intent is to fund educational initiatives that use multi-channel platforms

and reach a national audience. Educational initiatives hosted online or held live at national oncology conferences, associated regional and local meetings, as well as post-conference education, grand rounds, and patient-tethered education will be considered. Preference is for educational initiatives that are accredited (eg, by the ACCME, ANCC, ACPE, AANP, AAPA, etc).

Educational Outcomes:

Grants that are designed to measure improvements/changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*) are funding priorities.

Budget Available: The total available budget for this CGA is $1M. References: 1. NCCN Clinical Practice Guidelines In Oncology: Uterine Neoplasms.

Version 4.2019—September 16, 2019. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

2. De Felice F, Marchetti C, Tombolini V, et al. Int J Clin Oncol. 2019;24: 910-916. https://doi.org/10.1007/s10147-019-01437-7

3. Arend RC, Jones BA, Martinez A, et al. Gynecol Oncol. 2018;150:569-580. https://dx.doi.org/10.1016/j.ygyno.2018.05.015

4. Goebel EA, Vidal A, Matias-Guiu X, et al. Virchows Arch. 2018;472:885-896. http://dx.doi.org/10.1007/s00428-017-2279-8

5. Di Tucci C, Capone C, Galati G, et al. J Gynecol Oncol. 2019;30:e46. http://dx.doi.org/10.3802/jgo.2019.30.e46

6. NCCN Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicities. Version 2.2019—April 8, 2019. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf

7. Madden DL. Curr Oncol Rep. 2018;20:8. http://dx.doi.org/10.1007/s11912-018-0662-5.

GlaxoSmithKline Updated March 19, 2020 16

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

VACCINE PREVENTABLE DISEASES Please refer to Section III Grant Review Criteria (above) for more details about how grant applications will be reviewed.

Timeline: Grants may be submitted between November 18, 2019 and March 2, 2020, with a grant start date of May 15, 2020 or later.

Healthcare Gap(s): Our intent is to fund educational initiatives that are designed to close at least 1 of the following independently identified healthcare gaps; however, other independently identified healthcare gaps are also encouraged to be included: (1) Lack of understanding of the primary risk factors for shingles, specifically

focusing on the age-related decline in immunity and immunocompromised conditions1,2

(2) Lack of awareness of shingles disease burden, diagnosis, treatment, and prevention, including current vaccination recommendations3

(3) Strategies to improve uptake of vaccination and series completion for shingles, including improving the healthcare professional-patient dialogue around recommendations for the vaccine and setting realistic expectations for reactogenicity to maximize the potential for series completion4,5

(4) The application of behavioral insights and behavioral economic principles for increasing vaccine confidence6,7

(5) Challenges and solutions to implementing immunization across the life span8

(6) Vaccination as a contribution to a healthy lifestyle and a key piece in a multidisciplinary approach to healthy aging9,10

(7) Effective strategies for implementing meningococcal vaccination in practice (serogroups ACWY and B), including understanding vaccine recommendations and how to approach shared clinical decision-making11,12,13

(8) Understanding and communicating the importance of vaccine series completion in preventing invasive meningococcal disease (caused by serogroups ACWY and B)11,12

(9) Strategies to improve vaccine uptake in older adolescents, including the importance of pre-matriculation vaccination for incoming college students14

(10) Addressing adolescent and adult vaccine quality/performance measure gaps15,16,17

More Information: Our intent is to fund educational initiatives that use multi-channel platforms and reach a national or regional audience. Educational initiatives at national and statewide conferences will be considered. Preference is for educational initiatives that are accredited (eg, by the ACCME, ANCC, ACPE, AANP, AAPA, etc).

Educational Outcomes:

Grants that are designed to measure improvements/changes in HCP competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*) are funding minimal requirements.

GlaxoSmithKline Updated March 19, 2020 17

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

Budget Available: The total available budget for this CGA is $3.75M. References: 1. Gershon AA, Gershon MD, Breuer J, et al. J Clin Virol. 2010;48(Suppl

1):S2-S7. http://doi.org/10.1016/S1386-6532(10)70002-0 2. Poland GA, Ovsyannikova IG, Kennedy RB. Vaccine. 2017;S0264-

410X(17)30970-2. http://doi.org/10.1016/j.vaccine.2017.07.062 3. Paek E and Johnson R. Gerontology. 2010;56:20-31.

http://doi.org/10.1159/000240046 4. Opel DJ, Mangione-Smith R, Robinson JD, et al. Am J Public Health.

2015;105:1998-2004. http://doi.org/10.2105/AJPH.2014.302425 5. US Department of Health & Human Services (HHS) National Vaccine

Program Office National Adult Immunization Plan (NAIP). 2016. https://www.hhs.gov/sites/default/files/nvpo/national-adult-immunization-plan/naip.pdf

6. Buttenheim AM and Asch DA. JAMA Pediatr. 2016;170:635-636. https://doi.org/10.1001/jamapediatrics.2016.0192

7. Brewer NT, Chapman GB, Rothman AJ, et al. Psychol Sci in the Public Interest. 2017;18:149-207. https://doi.org/10.1177/1529100618760521

8. Philip RK, Attwell K, Breuer T, et al. Expert Rev Vaccines. 2018;17:851-864. https://doi.org/10.1080/14760584.2018.1527690

9. International Federation on Aging. Adult Vaccination: A Key Component of Healthy Ageing. 2013. http://www.ifa-fiv.org/wp-content/uploads/2015/09/SAATI-Report-2013.pdf

10. Doherty TM, Connolly MP, Del Giudice G, et al. Eur Geriatr Med. 2018;9:289-300. http://doi.org/10.1007/s41999-018-0040-8

11. Schaffner W, Baker CJ, Bozof L, et al. Infect Dis Clin Pract. 2014;22:245-252. http://dx.doi.org/10.1097/IPC.0000000000000197

12. Nolan T, O’Ryan M, Wassil J, et al. Vaccine. 2015;33:4437-4445. http://dx.doi.org/10.1016/j.vaccine.2015.06.011

13. Immunization Action Coalition Express Weekly News and Information. 2019. Issue 1436. https://www.immunize.org/express/issue1436.asp

14. Walker TY, Elam-Evans LD, Yankey D, et al. MMWR Morb Mortal Wkly Rep 2019;68:718–723. https://doi.org/10.15585/mmwr.mm6833a2

15. National Quality Forum. 2014. http://www.qualityforum.org/Publications/2014/08/Priority_Setting_for_Healthcare_Performance_Measurement__Addressing_Performance_Measure_Gaps_for_Adult_Immunizations.aspx

16. National Committee for Quality Assurance. HEDIS Measures and Technical Resources. 2019. https://www.ncqa.org/hedis/measures/

17. National Committee for Quality Assurance. HEDIS Adult and Prenatal Immunization Measures. 2019. https://www.ncqa.org/wp-content/uploads/2019/02/NCQA-AIS-PRS-Webinar-Slides-Feb-2019.pdf

GlaxoSmithKline Updated March 19, 2020 18

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

ORAL HEALTH Please refer to Section III Grant Review Criteria (above) for more details about how grant applications will be reviewed.

Timeline: Grants may be submitted between November 18, 2019 and March 2, 2020, with a grant start date of May 15, 2020 or later.

Healthcare Gap(s): Our intent is to fund educational initiatives that are designed to close at least 1 of the following independently identified healthcare gaps; however, other independently identified healthcare gaps are also encouraged to be included: (1) Lack of understanding of oral conditions such as acid erosion/wear, xerostomia,

periodontal disease, and oral conditions found in the edentulous1-5 (2) Appropriate understanding of available treatments to improve oral health and treat

disease1-5 More Information: Our intent is to fund educational initiatives that use multi-channel platforms and reach a

national or regional audience. Preference is for educational initiatives that are accredited (eg, by the APCE, AGD PACE, ADA CERP, etc).

Educational Outcomes:

Grants that are designed to measure improvements/changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*) are funding priorities.

Budget Available: Grant requests up to $50K will be considered for funding. The total available budget for this CGA is $200K.

References: 1. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. New Series of Reports to Monitor Health of Older Americans. 2010. http://www.cdc.gov/nchs/pressroom/01facts/olderame.htm

2. US Department of Health & Human Services (HHS), Office of Disease Prevention and Health Promotion (ODPHP). Healthy People 2020 Oral Health Objectives. https://www.healthypeople.gov/2020/topics-objectives/topic/oral-health/objectives

3. US Department of Health & Human Services (HHS), National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH). 2000. Oral Health in America: A Report of the Surgeon General. https://www.nidcr.nih.gov/DataStatistics/SurgeonGeneral/Documents/hck1ocv.@www.surgeon.fullrpt.pdf

4. Oral Health Foundation Denture Care Guidelines. 2018. https://www.dentalhealth.org/denturecareguidelines

5. American Dental Association Mouth Healthy. 2018. https://www.mouthhealthy.org/en

GlaxoSmithKline Updated March 19, 2020 19

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

PAIN-OSTEOARTHRITIS Please refer to Section III Grant Review Criteria (above) for more details about how grant applications will be reviewed.

Timeline: Grants may be submitted between November 18, 2019 and March 2, 2020, with a grant start date of May 15, 2020 or later.

Healthcare Gap(s): Our intent is to fund educational initiatives that are designed to close at least 1 of the following independently identified healthcare gaps; however, other independently identified healthcare gaps are also encouraged to be included: (1) Understanding of the scope of osteoarthritis (OA) including burden of

disease and comorbidities1-4 (2) OA diagnosis, assessment, and treatment5-7 (3) Treatment guidelines set forth by leading OA medical societies5,6 (4) Appropriate pain management strategies in OA with regard to patient

subpopulations (eg, comorbidities, age, disease state severity)2,3,5,8 More Information: Our intent is to fund educational initiatives that use multi-channel platforms

and reach a national audience. Educational initiatives at national and regional conferences will be considered. Preference is for educational initiatives that are accredited (eg, by the ACCME, ANCC, ACPE, AANP, AAPA, etc).

Educational Outcomes:

Grants that are designed to measure improvements/changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*) are funding priorities.

Budget Available: Grant requests up to $50K will be considered for funding. The total available budget for this CGA is $100K.

References: 1. Arthritis Foundation. Arthritis by the Numbers Book of Trusted Facts & Figures. 2018. https://www.arthritis.org/Documents/Sections/About-Arthritis/arthritis-facts-stats-figures.pdf

2. Breedveld FC. Rheumatology. 2004;43:i4-i8. https://doi.org/10.1093/rheumatology/keh102

3. Nelson AE. Osteoarthritis Cartilage. 2018;26:319-325. https://doi.org/10.1016/j.joca.2017.11.014

4. Palazzo C, Nguyen C, Lefevre-Colau MM, et al. Ann Phys Rehabil Med. 2016;59:134–138. https://doi.org/10.1016/j.rehab.2016.01.006

5. Bannuru RR, Osani MC, Vaysbrot EE, et al. Osteoarthritis Cartilage. 2019;27:1578-1589. https://doi.org/10.1016/j.joca.2019.06.011

6. Hochberg MC, Altman RD, April KT. Arthritis Care Res. 2012;64:465-474. https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.21596

7. McCarberg B and Tenzer P. Curr Med Res Opin. 2013;29:539-548. https://doi.org/10.1185/03007995.2013.785391

8. Pelletier JP, Martel-Pelletier J, Rannou F, et al. Semin Arthritis Rheum. 2016;45:S22-S27. https://doi.org/10.1016/j.semarthrit.2015.11.009

GlaxoSmithKline Updated March 19, 2020 20

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

PAIN-HEADACHE Please refer to Section III Grant Review Criteria (above) for more details about how grant applications will be reviewed.

Timeline: Grants may be submitted between November 18, 2019 and March 2, 2020, with a grant start date of May 15, 2020 or later.

Healthcare Gap(s): Our intent is to fund educational initiatives that are designed to close at least 1 of the following independently identified healthcare gaps; however, other independently identified healthcare gaps are also encouraged to be included: (1) Understanding of the epidemiology and burden of primary headache

disorders1,2 (2) Diagnosis, assessment, and differentiation of primary headache disorders

(eg, tension type, migraine, cluster)3-5 (3) Treatment guidelines and considerations for primary headache disorders3,6,7

More Information: Our intent is to fund educational initiatives that use multi-channel platforms and reach a national audience. Educational initiatives at national and regional conferences will be considered. Preference is for educational initiatives that are accredited (eg, by the ACCME, ANCC, ACPE, AANP, AAPA, etc).

Educational Outcomes:

Grants that are designed to measure improvements/changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*) are funding priorities.

Budget Available: Grant requests up to $50K will be considered for funding. The total available budget for this CGA is $100K.

References: 1. Dowson A. Int J Clin Pract. 2015;69(Suppl 182):S3-S7. https://doi.org/10.1111/ijcp.12650

2. Robbins MS and Lipton RB. Semin Neurol. 2010;30:107-119. https://doi.org/10.1055/s-0030-1249220

3. Bendtsen L. Ther Adv Neurol Disord. 2009;2:155-161. https://doi.org/10.1177/1756285609102328

4. The International Classification of Headache Disorders Cephalalgia. 2013;33:629-808. https://doi.org/10.1177/0333102413485658

5. Lipton RB, Cady RK, Stewart WF, et al. Neurology. 2002;58(Suppl 6): S27-S31. https://doi.org/10.1212/WNL.58.9_suppl_6.S27

6. Marmura MJ, Silberstein SD, Schwedt TJ. Headache. 2015;55:3-20 https://doi.org/10.1111/head.12499

7. Silberstein SD. Neurology. 2000; 55:754-762. https://doi.org/10.1212/wnl.55.6.754

GlaxoSmithKline Updated March 19, 2020 21

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

INFLUENZA Please refer to Section III Grant Review Criteria (above) for more details about how grant applications will be reviewed.

Timeline: Grants may be submitted between November 18, 2019 and March 2, 2020, with a grant start date of May 15, 2020 or later.

Healthcare Gap(s): Our intent is to fund educational initiatives that are designed to close at least 1 of the following independently identified healthcare gaps; however, other independently identified healthcare gaps are also encouraged to be included: (1) Lack of public understanding and awareness of influenza despite annual

education1-4 (2) Strategies to improve prevention through seasonal vaccination5-7 (3) Understanding the patient journey from self-identification to influenza

diagnosis to recovery8-10 (4) Understanding the purpose and utility of diagnostic tests11-13 (5) Decentralizing care and understanding the potential role of telemedicine

in delivering timely interventions to the influenza patient14-16 (6) Effective approaches to antiviral use and appreciating expected

outcome17-20 (7) Appropriate approaches to self-care and symptomatic treatment 21,22

More Information: Our intent is to fund educational initiatives that use multi-channel platforms and reach a national audience. Educational initiatives at national and regional conferences will be considered. Preference is for educational initiatives that are accredited (eg, by the ACCME, ANCC, ACPE, AANP, AAPA, etc).

Educational Outcomes:

Grants that are designed to measure improvements/changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*) are funding priorities.

Budget Available: Grant requests up to $50K will be considered for funding. The total available budget for this CGA is $50K.

References: 1. Hutchinson EC, Yamauchi Y. Methods Mol Biol. 2018;1836:1-21. https://doi.org/10.1007/978-1-4939-8678-1_1

2. Rogers CJ, Bahr KO, Benjamin SM. BMC Public Health. 2018;18:1131. https://doi.org/10.1186/s12889-018-6041-1

3. Ropero-Álvarez AM, El Omeiri N, Kurtis HJ, et al. Hum Vaccin Immunother. 2016;12:2206-2214. https://doi.org/10.1080/21645515.2016.1157240

4. Mayrhuber EA, Peersman W, van de Kraats N, et al. BMC Infect Dis. 2018;18:647. https://doi.org/10.1186/s12879-018-3568-9

5. Bekkat-Berkani R, Romano-Mazzotti L. Vaccine. 2018;36:7276-7285. https://doi.org/10.1016/j.vaccine.2018.10.027

6. Whitaker JA, von Itzstein MS, Poland GA. Vaccine. 2018;36:5940-5948. https://doi.org/10.1016/j.vaccine.2018.08.040

7. Grohskopf LA, Alyanak E, Broder KR, et al. MMWR Recomm Rep.

GlaxoSmithKline Updated March 19, 2020 22

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

2019;68:1-21. https://doi.org/10.15585/mmwr.rr6803a1 8. Chow EJ, Doyle JD, Uyeki TM. Crit Care. 2019;23:214.

https://doi.org/10.1186/s13054-019-2491-9 9. Uyeki TM. Influenza. Ann Intern Med. 2017;167:ITC33-ITC48. 10. Palekar RS, Rolfes MA, Arriola CS, et al. PLoS One. 2019;14:e0221479.

https://doi.org/10.1371/journal.pone.0221479 11. Seaman CP, Tran LTT, Cowling BJ, et al. J Clin Virol. 2019;118:28-35.

https://doi.org/10.1016/j.jcv.2019.07.010 12. Wenham C, Gray ER, Keane CE, et al. J Med Internet Res. 2018;20:e71.

https://doi.org/10.2196/jmir.9084 13. Yeo SJ, Choi K, Cuc BT, et al. Theranostics. 2016;6:231-242.

https://doi.org/10.7150/thno.14023 14. Rolland-Harris E, Mangtani P, Moore KM. Telemed J E Health.

2012;18:153-7. https://doi.org/10.1089/tmj.2011.0110 15. Sivey P, McAllister R, Vally H, et al. PLoS One. 2019;14:e0222851.

https://doi.org/10.1371/journal.pone.0222851 16. Morbey RA, Harcourt S, Pebody R, et al. Epidemiol Infect.

2017;145:1922-1932. https://doi.org/10.1017/S095026881700070X 17. Vogel GE. Med Microbiol Immunol. 2002;191:161-163.

https://doi.org/10.1007/s00430-002-0138-x 18. Jefferson T, Jones MA, Doshi P, et al. Cochrane Database Syst Rev.

2014;4:CD008965. https://doi.org/10.1002/14651858.CD008965.pub4 19. Louie JK, Lampiris H. JAMA Intern Med. 2015;175:1899-1900.

https://doi.org/10.1001/jamainternmed.2015.5747 20. Principi N, Camilloni B, Alunno A, et al. Front Med (Lausanne).

2019;6:109. https://doi.org/10.3389/fmed.2019.00109 21. Eccles R. J Clin Pharm Ther. 2006;31:309-319.

https://doi.org/10.1111/j.1365-2710.2006.00754.x 22. Klepser ME. Drugs. 2014;74:1467-1479. https://doi.org/10.1007/s40265-

014-0245-1

GlaxoSmithKline Updated March 19, 2020 23

*Moore DE, et al. J Contin Educ Health Prof. 2009;29:1-15.

SMOKING CESSATION Please refer to Section III Grant Review Criteria (above) for more details about how grant applications will be reviewed.

Timeline: Grants may be submitted between November 18, 2019 and March 2, 2020, with a grant start date of May 15, 2020 or later.

Healthcare Gap(s): Our intent is to fund educational initiatives that are designed to close at least 1 of the following independently identified healthcare gaps; however, other independently identified healthcare gaps are also encouraged to be included: (1) Smoking/tobacco use as a chronic, preventable disease1 (2) Availability of effective treatments to aid smoking cessation1-3 (3) Importance of treatment compliance2-4 (4) Importance of behavioral interventions when combined with approved

smoking cessation medications2-4

More Information: Our intent is to fund educational initiatives that use multi-channel platforms and reach a national or regional audience. Preference is for educational initiatives that are accredited (eg, by the ACCME, ANCC, ACPE, AANP, AAPA, etc).

Educational Outcomes:

Grants that are designed to measure improvements/changes in HCP knowledge (Level 3*), competence (Level 4*), performance (Level 5*), and/or patient/community health (Level 6/7*) are funding priorities.

Budget Available: Grant requests up to $50K will be considered for funding. The total available budget for this CGA is $50K.

References: 1. US Department of Health & Human Services (HHS), Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2014. A Report of the Surgeon General. http://www.surgeongeneral.gov/library/reports/50-years-of-progress/full-report.pdf

2. Okuyemi KS, Nollen NL, Ahluwalia JS. Am Fam Physician. 2006;74 262-271. doi

3. Fiore MC, Jaen CR, Baker TB, et al. US Department of Health & Human Services (HHS), Public Health Service. Respir Care. 2008;53:1217-1222. doi

4. Shiffman S. Addiction. 2007;102:809-814. https://doi.org/10.1111/j.1360-0443.2007.01791.x